溃疡性结肠炎内镜活动度本地与中心判读一致性:托法替布OCTAVE试验结果
基于OCTAVE项目四项研究,评估溃疡性结肠炎内镜Mayo内镜子评分(MES)中心与本地判读的一致性。结果显示中度至高度一致(κappa 0.54-0.62),但在多数时间点不一致时本地判读系统性低于中心判读,提示潜在偏倚;地理区域、CRP、部分Mayo评分和既往TNF拮抗剂失败与不一致相关。
要点
- 中心与本地MES判读呈中度至高度一致,κappa范围0.54-0.62。
- 多数时间点不一致时本地判读系统性低于中心判读,提示偏倚。
- 地理区域、CRP、部分Mayo评分和既往TNF拮抗剂失败与判读差异相关。
核心结论
- 中心与本地内镜判读呈中度至高度一致,但多数时间点不一致时本地判读系统性偏低,提示潜在偏倚。
研究设计与样本
- 基于OCTAVE项目诱导(OCTAVE Induction 1&2)、维持(OCTAVE Sustain)和开放标签长期扩展(OCTAVE Open)研究,采用κappa统计和Bowker检验评估中心与本地MES判读一致性,Logistic回归分析差异决定因素。
主要发现
- 筛查时一致率77.1%,κappa 0.62(95%CI 0.59-0.66);OCTAVE Induction 1&2第8周63.8%,κappa 0.62(95%CI 0.59-0.66)。
- OCTAVE Sustain第52周一致率55.6%,κappa 0.56(95%CI 0.50-0.62);OCTAVE Open第2个月诱导无应答者一致率59.9%,κappa 0.54(95%CI 0.48-0.60)。
- 不一致时,OCTAVE Induction 1&2第8周、OCTAVE Sustain第52周和OCTAVE Open第2个月本地判读系统性低于中心判读(Bowker's P < 0.0001);筛查时无此差异(P = 0.0852)。
- OCTAVE Induction 1&2第8周,地理区域、C反应蛋白、部分Mayo评分和既往TNF拮抗剂失败与判读差异相关(P < 0.05)。
- OCTAVE Induction 1&2和OCTAVE Sustain中,无论中心或本地判读,托法替布组内镜改善、缓解和内镜缓解比例均显著高于安慰剂组。
临床怎么用
- 临床试验中应关注本地与中心内镜判读的潜在不一致,尤其在不一致时本地判读偏低可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endoscopy is routine in trials of ulcerative colitis therapies. AIM: To investigate agreement between central and local Mayo endoscopic subscore (MES) reads in the OCTAVE programme METHODS: Flexible sigmoidoscopy was performed in tofacitinib induction (OCTAVE Induction 1&2, NCT01465763 and NCT01458951), maintenance (OCTAVE Sustain, NCT01458574) and open-label, long-term extension (OCTAVE Open, NCT01470612) studies. Kappa statistics and Bowker's tests evaluated agreement/disagreement between centrally and locally read MES, with potential determinants of differences analysed by logistic regression. RESULTS: Moderate-to-substantial agreement was observed between central and local reads at screening (77.1% agreement; kappa 0.62 [95% confidence interval 0.59-0.66]), OCTAVE Induction 1&2 week (Wk) 8 (63.8%; 0.62 [0.59-0.66]), OCTAVE Sustain Wk 52 (55.6%; 0.56 [0.50-0.62]) and for induction non-responders at OCTAVE Open month 2 (59.9%; 0.54 [0.48-0.60]). Where disagreements occurred, local reads were systematically lower than central reads at OCTAVE Induction 1&2 Wk 8, OCTAVE Sustain Wk 52 and OCTAVE Open month 2 (Bowker's P < 0.0001); this difference was not observed at screening (P = 0.0852). Using multivariable logistic regression, geographical region, C-reactive protein (Wk 8), partial Mayo score (Wk 8) and prior tumour necrosis factor antagonist failure were associated with disparity at OCTAVE Induction 1&2 Wk 8 (P < 0.05). In OCTAVE Induction 1&2 and OCTAVE Sustain, significantly higher proportions of patients endoscopic improvement, remission and endoscopic remission with tofacitinib vs placebo, using either central or local reads. CONCLUSION: Moderate-to-substantial agreement was observed between central and local endoscopic reads. Where disagreements occurred, local reads were systematically lower than central reads at most timepoints, suggesting potential bias. ClinicalTrials.gov identifier: NCT01465763, NCT01458951, NCT01458574, NCT01470612.
引用
- Feagan BG, Khanna R, Sandborn WJ, et al. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Aliment Pharmacol Ther. 2021. PMID: 34614208. doi:10.1111/apt.16626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。